rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IMRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Immuneering CFO Andrew Gengos buys $89,500 in shares
      Nov 16Investing.comIMRX
      Immuneering plans Phase 2 atebimetinib trial in anaplastic thyroid cancer
      Nov 12Yahoo FinanceIMRX
      Immuneering at guggenheim healthcare conference: pancreatic data in focus
      Nov 9Investing.comIMRX
      Immuneering presents preclinical data on atebimetinib combinations
      Nov 4Investing.comIMRX
      Immuneering stock price target maintained at $14 by H.C. Wainwright
      Oct 30Investing.comIMRX
      Immuneering presents phase 3 pancreatic cancer trial design
      Oct 26Investing.comIMRX
      Immuneering Has Promising Survival Data, Though Its Cash Discount Needs Scrutiny (IMRX)
      Oct 19Seeking AlphaIMRX
      Immuneering at H.C. Wainwright conference: pancreatic cancer push
      Sep 14Investing.comIMRX
      Immuneering at cantor healthcare conference: pancreatic cancer bet gains focus
      Sep 10Investing.comIMRX
      Immuneering to Participate in Upcoming Investor Conferences

      NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management plans to participate in the following upcoming investor conferences: Cantor Global Healthcare Conference (September 9-11 in New York City) Format: Fireside Chat and 1x1 Investor MeetingsDate/Time: Thursday, September 10, 2026, from 2:45-3:15 pm ET H.C. Wainwright 28th Annual Gl

      Sep 3Yahoo FinanceIMRX
      H.C. Wainwright reiterates Immuneering stock rating on MEK pathway potential
      Aug 27Investing.comIMRX
      Immuneering comments on FDA pancreatic cancer drug approval
      Aug 26Investing.comIMRX
      Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

      Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

      Aug 26BarchartIMRX

      This is the newest page. Registered accounts read further back.